Clinical Trial Update: Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP) [Phase 1]

View source ↗

Summary

A phase 1 safety study of GMA161 in patients with idiopathic thrombocytopenic purpura has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• GMA161

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Idiopathic Thrombocytopenic Purpura | Phase 1 | Status: TERMINATED